Prodrugs pp 965-988 | Cite as

Functional Group Approaches to Prodrugs: Functional Groups in Peptides

  • Hao Fang
  • Gurpreet Kaur
  • Binghe Wang
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)


There is no doubt that peptides play critical roles in various biological processes. Naturally, a large number of biologically active peptides have been discovered, many of which are clinically used pharmaceutical agents. However, there are intrinsic physicochemical and pharmaceutical properties associated with peptides that hinder their development as oral- and CNS-active pharmaceutical agents. These properties include high polarity and hydrogen-bonding potential, and the presence of charged functional groups, all of which are significant contributing factors to the generally poor permeation properties of peptides across membrane barriers. In addition, peptides typically undergo rapid metabolism, which leads to short half-lives in vivo (<30 min). Consequently, peptides are generally considered poor candidates for development as orally and CNS-active pharmaceutical agents. Although the fundamental stability issues can sometimes be addressed with structural modifications and the introduction of Damino acids, the poor membrane permeation is generally intrinsic to the peptide structural features. One way to overcome this problem is the prodrug approach, i.e., to temporarily and bioreversibly mask those functional groups responsible for the undesirable physicochemical and pharmaceutical properties of peptides (Audus et al., 1995; Borchardt, 1995; Artursson and Borchardt, 1997; Gangwar et al., 1997b; Pauletti et al., 1997a; Shan et al., 1997; Wang et al., 1999c).


Opioid Peptide Parent Peptide Phenylpropionic Acid Prodrug Approach Intramolecular Hydrogen Bond Formation 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Artursson P, and Borchardt RT. Intestinal Drug Absorption and Metabolism in Cell Cultures: Caco-2 and Beyond. Pharm Res 1997; 14:1655–1658PubMedCrossRefGoogle Scholar
  2. Audus K, Ng L, Wang W, and Borchardt RT. Brain Microvessel Endothelial Cell Culture Systems. In: Borchardt RT, Wilson G, and Smith P. Model Systems Used for Biopharmaceutical Assessment of Drug Absorption and Metabolism. New York, Plenum Press; 1996:239–258Google Scholar
  3. Bak A, Gudmundsson O, Friis GJ, Siahaan TJ, and Borchardt RT. Acyloxyalkoxy-Based Cyclic Prodrugs of Opioid Peptides: Evaluation of the Chemical and Enzymatic Stability as well as Their Transport Properties across Caco-2 Cell Monolayers. Pharm Res 1999a; 16:24–29PubMedCrossRefGoogle Scholar
  4. Bak A, Siahaan TJ, Gudmundsson OS, Gangwar S, Friis GJ, and Borchardt RT. Synthesis and Evaluation of the Physicochemical Properties of Esterase-Sensitive Cyclic Prodrugs of Opioid Peptides Using an Acyloxyalkoxy Linker. J Peptide Res 1999b; 53:393–402CrossRefGoogle Scholar
  5. Borchardt RT. The Application of Cell Culture Systems in Drug Discovery and Development. J Drug Targeting 1995; 3:179–182CrossRefGoogle Scholar
  6. Borchardt RT, and Cohen LA. Stereopopulation Control. III. Facilitation of Intramolecular Conjugate Addition of the Carboxyl Group. J Am Chem Soc 1972; 94:9175–9182PubMedCrossRefGoogle Scholar
  7. Borchardt RT, and Wang W. Prodrug Strategies to Improve the Oral Absorption of Peptides and Peptide Mimetics. In: Park K, and Mrsny RJ. Drug Delivery in the 21st Century. Washington, DC, American Chemical Society; 2000:36–45Google Scholar
  8. Bundgaard H, and Rasmussen GJ. Prodrugs of Peptides. 9. Bioreversible N-α-Hydroxyalkylation of the Peptide Bond to Effect Protection against Carboxypeptidase or Other Proteolytic Enzymes. Pharm Res 1991a; 8:313–322PubMedCrossRefGoogle Scholar
  9. Bundgaard H, and Rasmussen GJ. Prodrugs of Peptides. 11. Chemical and Enzymatic Hydrolysis Kinetics of N-Acyloxymethyl Derivatives of a Peptide-like Bond. Pharm Res 1991b; 81238–1242Google Scholar
  10. Burton PS, Conradi RA, Hilgers RA, Ho NFH, and Maggiora LL. The Relationship between Peptide Structure and Transport Across Epithelial Cell Monolayers. J Control Release 1992; 9:87–98CrossRefGoogle Scholar
  11. Burton PS, Conradi RA, Ho NF, Hilgers AR, and Borchardt RT. How Structural Features Influence the Biomembrane Permeability of Peptides. J Pharm Sci 1996; 85:1336–1340PubMedCrossRefGoogle Scholar
  12. Buur A, and Bundgaard H. Prodrugs of Peptides. III. 5-Oxazolidinones as Biorevesible Derivatives for the α-Amidocarboxy Moiety in Peptides. Int J Pharm 1988; 46:159–167CrossRefGoogle Scholar
  13. Camenisch GP, Wang W, Wang B, and Borchardt RT. A Comparison of the Bioconversion Rates and the Caco-2 Cell Permeation Characteristics of Coumarin-Based Cyclic Prodrugs and Methylester Linear Prodrugs of RGD Peptidomimetics. Pharm Res 1998; 15:1174–1187PubMedCrossRefGoogle Scholar
  14. Chikhale EG, Ng KY, Burton PS, and Borchardt RT. Hydrogen Bonding Potential as a Determinant of the in vitro and in situ Blood Brain Barrier Permeability of Peptides. Pharm Res 1994; 11:412–419PubMedCrossRefGoogle Scholar
  15. Conradi RA, Hilgers AR, Ho NFH, and Burton PS. The Influence of Peptide Structure on Transport Across Caco-2 Cells. II. Peptide Bond Modification which Results in Improved Permeability. Pharm Res 1992; 9:435–439PubMedCrossRefGoogle Scholar
  16. Fentem JH, Hammond AH, Garle M, and Fry JR. Toxicity of Coumarin and Various Methyl Derivatives in Cultures of Rat Hepatocytes and V79 Cells. Toxicol In Vitro 1992; 6:21–25CrossRefGoogle Scholar
  17. Fentem JH, and Fry JR. Species Difference in the Metabolism and Hepatotoxicity of Coumarin. Comp Biochem Physiol 1993; 104C:1–8Google Scholar
  18. Friis GJ, Bak A, Larsen BD, and Frokjær S. Prodrugs of Peptides Obtained by Derivatization of the C-Terminal Peptide Bond in Order to Effect Protection Against Degradation by Carboxypeptidases. Int J Pham 1996; 136:61–69CrossRefGoogle Scholar
  19. Gangwar S, Jois SDS, Siahaan TJ, Vander Velde D, Stella VJ, and Borchardt RT. The Effect of Conformation on Membrane Permeability of an Acyloxyalkoxy-linked Cyclic Prodrug of a Model Hexapeptide. Pharm Res 1996; 13:1655–1660CrossRefGoogle Scholar
  20. Gangwar S, Pauletti GM, Siahaan TJ, Stella VJ, and Borchardt RT. Synthesis of a Novel Esterase-sensitive Cyclic Prodrug of a Hexapeptide Using an Acyloxyalkoxy Promoiety. J Org Chem 1997a; 62:1356–1362CrossRefGoogle Scholar
  21. Gangwar S, Pauletti GM, Wang B, Siahaan T, Stella VJ, and Borchardt RT. Prodrug Strategies to Enhance the Intestinal Absorption of Peptides. Drug Discovery Today 1997b; 2:148–155CrossRefGoogle Scholar
  22. Gudmundsson O, Jois SDS, Vander Velde D, Siahaan TJ, Wang B, and Borchardt RT. The Effect of Conformation on the Membrane Permeability of Coumarinic Acid-and Phenylpropionic Acid-based Cyclic Prodrugs of Opioid Peptides. J Peptide Res 1999a; 53:383–392CrossRefGoogle Scholar
  23. Gudmundsson O, Pauletti GM, Wang W, Shan D, Zhang H, Wang B, and Borchardt RT. Coumarinic Acid-Based Cyclic Prodrugs of Opioid Peptides that Exhibit Metabolic Stability to Peptidases and Excellent Cellular Permeability. Pharm Res 1999b; 16:7–15PubMedCrossRefGoogle Scholar
  24. Gudmundsson OS, Nimkar K, Gangwar S, Siahaan TJ, and Borchardt RT. Phenylpropionic Acid-Based Cyclic Prodrugs of Opioid Peptides that Exhibit Metabolic Stability to Peptidases and Excellent Cellular Permeability. Pharm Res 1999c; 16:16–23PubMedCrossRefGoogle Scholar
  25. Hamada Y, Ohtake J, Sohma Y, Kimura T, Hayashi Y, and Kiso Y. New Water-Soluble Prodrugs of HIV Protease Inhibitors Based on O,N Intramolecular Acyl Migration. Bioorg Med Chem 2002; 10:4155–4167PubMedCrossRefGoogle Scholar
  26. Hamada Y, Matsumoto H, Kimura T, Hayashi Y, and Kiso Y. Effect of the Acyl Groups on O,N Acyl Migration in the Water-Soluble Prodrugs of HIV-1 Protease Inhibitor. Bioorg Med Chem Lett 2003; 13:2727–2730PubMedCrossRefGoogle Scholar
  27. Hamada Y, Matsumoto H, Yamaguchi S, Kimura T, Hayashi Y, and Kiso Y. Water-Soluble Prodrugs of Dipeptide HIV Protease Inhibitors Based on O,N Intramolecular Acyl Migration: Design, Synthesis and Kinetic Study. Bioorg Med Chem 2004; 12:159–170PubMedCrossRefGoogle Scholar
  28. Hillery PS, and Cohen LA. Stereopopulation Control. 9. Rate and Equilibrium Enhancement in the Lactonization of (o-Hydroxyphenyl)acetic Acid. J Org Chem 1983; 48:3465–3471CrossRefGoogle Scholar
  29. Ho NF, Raub TR, Burton PS, Barsuhn CL, Adson A, Audus KL, and Borchardt RT. Transport Processes in Pharmaceutical Systems. In: Amidon GL, Lee PI, and Topp EM. Quantitative Approaches to Delineate Transport Mechanisms in Cell Culture Monolayers. New York, Marcel Dekker; 1999:219–316Google Scholar
  30. Hurley TR, Colson CE, Hicks G, and Ryan MJ. Orally Active Water-Soluble N,OAcyl Transfer Products of a β,α-Bishydroxyl Amide Containing Renin Inhibitor. J Med Chem 1993; 36:1496–1498PubMedCrossRefGoogle Scholar
  31. Kim DC, Burton PS, and Borchardt RT. A Correlation Between the Permeability Characteristics of a Series of Peptides Using an in vitro Cell Culture Model (Caco-2) and an in situ Perfused Rat Ileum Model of the Intestinal Mucosa. Pharm Res 1993; 10:1710–1714PubMedCrossRefGoogle Scholar
  32. Liao Y, and Wang B. Substituted Coumarins as Esterase-sensitive Prodrug Moieties with Improved Release Rates. Bioorg Med Chem Lett 1999; 9:1795–1800PubMedCrossRefGoogle Scholar
  33. Liao Y, Hendrata S, Bae SY, and Wang B. The Effect of Phenyl Substituents on the Release Rates of Esterase-Sensitive Coumarin-Based Prodrugs. Chem Pharm Bull 2000; 48:1138–1147PubMedGoogle Scholar
  34. Milstein S, and Cohen L. Rate Acceleration by Stereopopulation Control: Models for Enzyme Action. Proc Nat Acad Sci US 1970; 67:1143–1147CrossRefGoogle Scholar
  35. Milstein S, and Cohen LA. Stereopopulation Control. I. Rate Enhancement in the Lactonization of o-Hydroxyhydrocinnamic Acids. J Am Chem Soc 1972;94:9158–9165CrossRefGoogle Scholar
  36. National Toxicology Program Toxicology and Carcinogenesis. Studies of Coumarin; U.S. Department of Health and Human Services: Public Health Service and National Institutes of Health, 1993.Google Scholar
  37. Oliyai R. Prodrugs of Peptides and Peptidomimetics for Improved Formulation and Delivery. Adv Drug Del Rev 1996; 19:275–286CrossRefGoogle Scholar
  38. Oliyai R, and Stella VJ. Kinetics and Mechanism of Isomerization of Cyclosporin A. Pharm Res 1992; 9:617–622PubMedCrossRefGoogle Scholar
  39. Oliyai R, and Stella VJ. Prodrugs of Peptides and Proteins for Improved Formulation and Delivery. Annu Rev Pharmacol Toxicol 1993; 32:521–544CrossRefGoogle Scholar
  40. Oliyai R, and Stella VJ. Structural Factors Affecting the Kinetics of O,N-acyl Transfer in Potential O-Peptide Prodrugs. Bioorg Med Chem Lett 1995;5:2735–2740CrossRefGoogle Scholar
  41. Oliyai R, Safadi M, Meier PG, Hu M-K, Rich DH, and V.J. S. Kinetics of Acid Catalyzed Degradation of Cyclosporin A and its Analogs in Aqueous Solution. Int J Peptide Protein Res 1994; 43:239–247Google Scholar
  42. Oliyai R, Siahaan TJ, and Stella VJ. The Importance of Structural Factors on the Rate and the Extent of N,O-Acyl Migration in Cyclic and Linear Peptides. Pharm Res 1995; 12:323–328PubMedCrossRefGoogle Scholar
  43. Pauletti GM, Gangwar S, Okumu FW, Siahaan TJ, Stella VJ, and Borchardt RT. Esterase-sensitive Cyclic Prodrugs of Peptides: Evaluation of an Acyloxyalkoxy Promoiety in a Model Hexapeptide. Pharm Res 1996; 13:1613–1621CrossRefGoogle Scholar
  44. Pauletti GM, Gangwar S, Siahaan TJ, Aubé J, and Borchardt RT. Improvement of Oral Peptide Bioavailability: Peptide Mimetics and Prodrug Strategies. Adv Drug Del Rev 1997a; 27:235–256CrossRefGoogle Scholar
  45. Pauletti GM, Gangwar S, Wang B, and Borchardt RT. Esterase-Sensitive Cyclic Prodrugs of Peptides: Evaluation of a Phenylpropionic Acid Promoiety in a Model Hexapeptide. Pharm Res 1997b; 14:11–17PubMedCrossRefGoogle Scholar
  46. Pelkonen O, Raunio H, Rautio A, Pasanen M, and Lang MA. The Metabolism of Coumarin. In: O’Kennedy R, and Thornes RD, Coumarins Biology, Applications and Mode of Action. New York, John Wiley & Sons; 1997:67–92Google Scholar
  47. Shan D, Nicolaou MG, Borchardt RT, and Wang B. Prodrug Strategies Based on Intramolecular Cyclization Reactions. J Pharm Sci 1997; 86:765–767PubMedCrossRefGoogle Scholar
  48. Van Iersel ML, Henderson CJ, Walters DG, Price RJ, and Lake BG. Metabolism of (3–14C)Coumarin by Human Liver Microsomes. Xenobiotica 1994; 24:795–803PubMedCrossRefGoogle Scholar
  49. Wang B, Zhang H, and Wang W. Chemical Feasibility Studies of a Potential Coumarin-Based Prodrug System. Bioorg Med Chem Lett 1996a; 6:945–950CrossRefGoogle Scholar
  50. Wang B, Wang W, Zhang H, Shan D, and Smith TD. Coumarin-Based Prodrugs 2. Synthesis and Bioreversibility Studies of an Esterase-Sensitive Cyclic Prodrug of DADLE, an Opioid Peptide. Bioorg Med Chem Lett 1996b; 6:2823–2826CrossRefGoogle Scholar
  51. Wang B, Gangwar S, Pauletti GM, Siahaan T, and Borchardt RT. Synthesis of a Novel Esterase-Sensitive Cyclic Prodrug System for Peptides that Utilizes a “Trimethyl Lock”-Facilitated Lactonization Reaction. J Org Chem 1997;62:1363–1367CrossRefGoogle Scholar
  52. Wang B, Zhang H, Zheng A, and Wang W. Coumarin-Based Prodrugs 3. Structural Effects on the Release Kinetics of Esterase-Sensitive Prodrugs of Amines. Bioorg Med Chem 1998; 6:417–426PubMedCrossRefGoogle Scholar
  53. Wang B, Nimkar K, Wang W, Zhang H, Shan D, Gudmundsson O, Gangwar S, Siahaan T, and Borchardt RT. Synthesis and Evaluation of the Physicochemical Properties of Esterase-Sensitive Cyclic Prodrugs of Opioid Peptides Using Coumarinic Acid and Phenylpropionic Acid Linkers. J Peptide Res 1999a;53:370–382CrossRefGoogle Scholar
  54. Wang B, Wang W, Camenisch GP, Elmo J, Zhang H, and Borchardt RT. Synthesis and Evaluation of Novel Coumarin-Based Esterase-Sensitive Cyclic Prodrugs of Peptidomimetic RGD Analogs with Improved Membrane Permeability. Chem Pharm Bull 1999b; 47:90–95PubMedGoogle Scholar
  55. Wang W, Jiang J, Ballard CE, and Wang B. Prodrug Approaches to the Improved Delivery of Peptide Drugs. Current Pharm Design 1999c; 5:265–287Google Scholar
  56. Zheng A, Wang W, Zhang H, and Wang B. Two New Improved Approaches to the Synthesis of Coumarin-Based Prodrugs. Tetrahedron 1999; 55:4237–4254CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Hao Fang
    • 1
  • Gurpreet Kaur
    • 2
  • Binghe Wang
    • 2
  1. 1.College of PharmacyShandong UniversityJinan, ShandongChina
  2. 2.Department of Chemistry and Center for Biotechnology and Drug DesignGeorgia State UniversityAtlantaUSA

Personalised recommendations